Protara Therapeutics, Inc. (TARA) Free cash flow 2016–2025
Protara Therapeutics, Inc. (TARA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$56.5MFY2025 · since FY2016: -$24.0M → -$56.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$56.5M | -57.4% |
| FY2024 | -$35.9M | +4.6% |
| FY2023 | -$37.6M | -41.5% |
| FY2022 | -$26.6M | +24.3% |
| FY2021 | -$35.1M | -44.5% |
| FY2020 | -$24.3M | -342.8% |
| FY2019 | -$5.5M | +76.5% |
| FY2018 | -$23.4M | -4.3% |
| FY2017 | -$22.4M | +6.6% |
| FY2016 | -$24.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TARA financial trends
TARA RevenueTARA Net incomeTARA Net marginTARA Gross profitTARA Gross marginTARA Operating incomeTARA Operating marginTARA Operating cash flowTARA Capital expendituresTARA Return on equityTARA Stock buybacksTARA Dividends paidTARA Total assetsTARA Total liabilitiesTARA Shareholders’ equityTARA overview →